Clinical and HLA Genotype Analysis of Immune Checkpoint Inhibitor-associated Diabetes Mellitus: a Single-center Case Series from China

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jun 26

PMID 37359544

Authors

Yi-Chen Liu

Hong Liu

Shao-Li Zhao

Ke Chen

Ping Jin

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the clinical characteristics and HLA genotypes of patients with immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) in China.

Methods: We enrolled 23 patients with ICI-DM and 51 patients with type 1 diabetes (T1D). Clinical characteristics of the patients were collected. HLA-DRB1, HLA-DQA1, and HLA-DQB1 genotyping was conducted via next-generation sequencing.

Results: The ICI-DM patients had a male predominance (70.6%), a mean body mass index (BMI) of 21.2 ± 3.5 kg/m, and a mean onset of ICI-DM in 5 (IQR, 3-9) cycles after ICI therapy. Most (78.3%) ICI-DM patients were treated with anti-PD-1, 78.3% presented with diabetic ketoacidosis, and all had low C-peptide levels and received multiple insulin injections. Compared to T1D patients, ICI-DM patients were significantly older (57.2 ± 12.4 34.1 ± 15.7 years) and had higher blood glucose but lower HbA1c levels (<0.05). Only two (8.7%) ICI-DM patients were positive for islet autoantibodies, which was lower than that in T1D patients (66.7%, P<0.001). A total of 59.1% (13/22) of ICI-DM patients were heterozygous for an HLA T1D risk haplotype, and DRB1*0901-DQA1*03-DQB1*0303 (DR9) and DRB1*0405-DQA1*03-DQB1*0401 were the major susceptible haplotypes. Compared to T1D, the susceptible DR3-DQA1*0501-DQB1*0201 (DR3) and DR9 haplotypes were less frequent (17.7% 2.3%; =0.011 and 34.4% 15.9%; =0.025), whereas the protective haplotypes (DRB1*1101-DQA1*05-DQB1*0301 and DRB1*1202-DQA1*0601-DQB1*0301) were more frequent in ICI-DM patients (2.1% 13.6%; =0.006 and 4.2% 15.9%; =0.017). None of the ICI-DM patients had T1D-associated high-risk genotypes DR3/DR3, DR3/DR9, and DR9/DR9. Among the 23 ICI-DM patients, 7 (30.4%) presented with ICI-associated fulminant type 1 diabetes (IFD), and 16 (69.6%) presented with ICI-associated type 1 diabetes (IT1D). Compared to IT1D patients, IFD patients exhibited marked hyperglycemia and low C-peptide and HbA1c levels (<0.05). Up to 66.7% (4/6) of IFD patients were heterozygous for reported fulminant type 1 diabetes susceptibility HLA haplotypes (DRB1*0405-DQB1*0401 or DRB1*0901-DQB1*0303).

Conclusion: ICI-DM shares similar clinical features with T1D, such as acute onset, poor islet function and insulin dependence. However, the lack of islet autoantibodies, the low frequencies of T1D susceptibility and high frequencies of protective HLA haplotypes indicate that ICI-DM represents a new model distinct from classical T1D.

Citing Articles

Clinical characteristics and unique presentations of immune checkpoint inhibitor induced type 1 diabetes in Chinese patients from a single institution.

Liu W, Li C, Fang Y, Cai X, Zhu Y, Ren Q Sci Rep. 2025; 15(1):5339.

PMID: 39948427 PMC: 11825683. DOI: 10.1038/s41598-025-89668-9.

Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association.

Kamitani F, Nishioka Y, Koizumi M, Nakajima H, Kurematsu Y, Okada S J Diabetes Investig. 2024; 16(2):334-342.

PMID: 39569589 PMC: 11786175. DOI: 10.1111/jdi.14362.

Immune checkpoint inhibitors-induced diabetes mellitus (review).

Chen J, Hou X, Yang Y, Wang C, Zhou J, Miao J Endocrine. 2024; 86(2):451-458.

PMID: 38955861 DOI: 10.1007/s12020-024-03942-w.

Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.

Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T Front Endocrinol (Lausanne). 2024; 15:1407192.

PMID: 38841300 PMC: 11150800. DOI: 10.3389/fendo.2024.1407192.

References

Quandt Z, Young A, Anderson M . Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020; 200(2):131-140. PMC: 7160652. DOI: 10.1111/cei.13424. View

Noble J, Valdes A, Cook M, Klitz W, Thomson G, Erlich H . The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996; 59(5):1134-48. PMC: 1914851. View

Luo S, Lin J, Xie Z, Xiang Y, Zheng P, Huang G . HLA Genetic Discrepancy Between Latent Autoimmune Diabetes in Adults and Type 1 Diabetes: LADA China Study No. 6. J Clin Endocrinol Metab. 2016; 101(4):1693-700. DOI: 10.1210/jc.2015-3771. View

Kotwal A, Haddox C, Block M, Kudva Y . Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019; 7(1):e000591. PMC: 6398813. DOI: 10.1136/bmjdrc-2018-000591. View

Telo G, Carvalhal G, Cauduro C, Webber V, Barrios C, Fay A . Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma. Ann Oncol. 2017; 28(1):191-192. DOI: 10.1093/annonc/mdw447. View

Knip M, Kukko M, Kulmala P, Veijola R, Simell O, Akerblom H . Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet. 2002; 115(1):48-54. DOI: 10.1002/ajmg.10343. View

Xia Y, Li X, Huang G, Lin J, Luo S, Xie Z . The association of HLA-DP loci with autoimmune diabetes in Chinese. Diabetes Res Clin Pract. 2020; 173:108582. DOI: 10.1016/j.diabres.2020.108582. View

Marchand L, Thivolet A, Dalle S, Chikh K, Reffet S, Vouillarmet J . Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol. 2018; 56(4):441-448. DOI: 10.1007/s00592-018-1234-8. View

Peng Y, Li X, Xiang Y, Yan X, Zhou H, Tang X . GAD65 Antibody Epitopes and Genetic Background in Latent Autoimmune Diabetes in Youth (LADY). Front Immunol. 2022; 13:836952. PMC: 8982141. DOI: 10.3389/fimmu.2022.836952. View

10.

Kawasaki E, Matsuura N, Eguchi K . Type 1 diabetes in Japan. Diabetologia. 2006; 49(5):828-36. DOI: 10.1007/s00125-006-0213-8. View

11.

Saito D, Oikawa Y, Yano Y, Ikegami Y, Satomura A, Isshiki M . Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes. Diabetes Care. 2019; 42(3):e40-e41. DOI: 10.2337/dc18-1673. View

12.

Tsang V, McGrath R, Clifton-Bligh R, Scolyer R, Jakrot V, Guminski A . Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. J Clin Endocrinol Metab. 2019; 104(11):5499-5506. DOI: 10.1210/jc.2019-00423. View

13.

Barroso-Sousa R, Barry W, Garrido-Castro A, Hodi F, Min L, Krop I . Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2017; 4(2):173-182. PMC: 5838579. DOI: 10.1001/jamaoncol.2017.3064. View

14.

Mayr A, Schlosser M, Grober N, Kenk H, Ziegler A, Bonifacio E . GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes. 2007; 56(6):1527-33. DOI: 10.2337/db06-1715. View

15.

Nishimura Y, Oiso M, Fujisao S, Kanai T, Kira J, Chen Y . Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune diseases. Int Rev Immunol. 1999; 17(5-6):229-62. DOI: 10.3109/08830189809054404. View

16.

Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Huang Y . Reporting of Immune Checkpoint Inhibitor Therapy-Associated Diabetes, 2015-2019. Diabetes Care. 2020; 43(7):e79-e80. PMC: 7305010. DOI: 10.2337/dc20-0459. View

17.

Qiu J, Luo S, Yin W, Guo K, Xiang Y, Li X . Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin. Front Immunol. 2022; 13:968798. PMC: 9702060. DOI: 10.3389/fimmu.2022.968798. View

18.

Baden M, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y . Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019; 10(1):58-66. PMC: 6357237. DOI: 10.1007/s13340-018-0362-2. View

19.

Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H . Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2014; 3(6):536-9. PMC: 4015434. DOI: 10.1111/jdi.12024. View

20.

Park Y, She J, Wang C, Lee H, Babu S, Erlich H . Common susceptibility and transmission pattern of human leukocyte antigen DRB1-DQB1 haplotypes to Korean and Caucasian patients with type 1 diabetes. J Clin Endocrinol Metab. 2001; 85(12):4538-42. DOI: 10.1210/jcem.85.12.7024. View